Please turn JavaScript on
header-image

ProMIS Neurosciences, Inc. (PMN) Press Releases

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  0.04 / day

Message History

Key Data (from BriefGlance.com) Two novel vaccine candidates unveiled for ALS and Parkinson's disease, targeting misfolded T...

Read full story

Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that it will present two scientific posters at the Alzheimer’s & Parkinson’s Diseases Conferenc...


Read full story

Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the company will be participating in a fireside chat and investor one-on-one meetings at the Guggenheim...


Read full story

Extends cash runway into 2028

Proceeds expected to enable completion of ProMIS’ landmark  Phase 1b AD study and support execution of key clinical milestones

Blinded 6-month top-line data expected mid-2026; 12-month top-line data expected toward end of 2026

CAMBRIDGE, M...


Read full story

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease

Clear and near-term value inflection points, with blinded 6-month interim data expected in Q2 2026 and final unblinded top-line results anticipated in Q4 2026

Cambridge, Massachusetts...


Read full story